Article Text

Download PDFPDF
Sublingual immunotherapy with a grass allergen tablet improved symptoms and quality of life in allergic rhinoconjunctivitis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with grass pollen-induced allergic rhinoconjunctivitis, how effective is sublingual immunotherapy with a grass allergen tablet?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Allergy & immunology ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial.

Embedded ImageAllocation:

unclear allocation concealment.*

Embedded ImageBlinding:

blinded (patients, healthcare providers, and outcome assessors).*

Embedded ImageFollow up period:

up to the end of grass pollen season.

Embedded ImageSetting:

55 centres in Canada, UK, Germany, Belgium, Austria, Denmark, Sweden, and Norway.

Embedded ImagePatients:

855 patients 18–65 years of age (mean age 35 y, 62% men) who had allergic rhinoconjunctivitis during grass pollen season for ⩾2 years and positive result on skin prick test to timothy grass (Phleum pratense). Exclusion criteria included history of asthma, anaphylaxis, or angio-oedema; forced expiratory volume1 <70% predicted; non-grass induced allergic rhinitis; recurrent acute or chronic sinusitis; conjunctivitis, rhinitis, or asthma at randomisation; hypersensitivity to trial medication; and immunotherapy for allergens in the past 5–10 years.

Embedded ImageIntervention:

oral P pratense …

View Full Text


  • * See glossary.

  • For correspondence: Dr S R Durham, Royal Brompton and Harefield Hospitals National Health Service Trust, London, UK. s.durham{at}

  • Source of funding: ALK-Abelló.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd